Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient prognosis. Materials and Methods We analyzed 125 patients with R/M HNSCC who received ICIs, retrospectively. Overall response rate (ORR) was the primary study outcome. Overall survival (OS) and progression-free survival (PFS) were the secondary study outcomes. Results The patients received anti–programmed cell death protein-1 (PD-1) (n=73, 58%), anti–programmed death-ligand 1 (PD-L1) (n=24, 19%), or a combination of anti–PD-1/PD-L1 and anti–cytotoxic T-lymphocyte antigen 4 (n=28, 22%). The median age was 57 years (range, 37 to 87). The location of the primary tumor was in the oral cavity in 28% of the cases, followed by oropharynx (27%), hypopharynx (20%), and larynx (12%). The ORR was 15% (19/125). With 12.3 months of median follow-up, median PFS was 2.7 months. Median OS was 10.8 months. A neutrophil-to-lymphocyte ratio (NLR) > 4 was significantly associated with poor response to ICIs (odds ratio, 0.30; p=0.022). A sum of the target lesions > 40 mm (hazard ratio [HR], 1.53; p=0.046] and a NLR > 4 (HR, 1.75; p=0.009) were considered to be predictive markers of short PFS. A poor performance status (HR, 4.79; p < 0.001), a sum of target lesions > 40 mm (HR, 1.93; p=0.025), and an NLR > 4 (HR, 3.36; p < 0.001) were the significant predictors for poor survival. Conclusion ICIs exhibited favorable antitumor activity in R/M HNSCC. Clinically, our findings can be used to recognize patients benefit from receiving ICI.
Abstract
Purpose This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient prognosis. Materials and Methods We analyzed 125 patients with R/M HNSCC who received ICIs, retrospectively. Overall response rate (ORR) was the primary study outcome. Overall survival (OS) and progression-free survival (PFS) were the secondary study outcomes. Results The patients received anti–programmed cell death protein-1 (PD-1) (n=73, 58%), anti–programmed death-ligand 1 (PD-L1) (n=24, 19%), or a combination of anti–PD-1/PD-L1 and anti–cytotoxic T-lymphocyte antigen 4 (n=28, 22%). The median age was 57 years (range, 37 to 87). The location of the primary tumor was in the oral cavity in 28% of the cases, followed by oropharynx (27%), hypopharynx (20%), and larynx (12%). The ORR was 15% (19/125). With 12.3 months of median follow-up, median PFS was 2.7 months. Median OS was 10.8 months. A neutrophil-to-lymphocyte ratio (NLR) > 4 was significantly associated with poor response to ICIs (odds ratio, 0.30; p=0.022). A sum of the target lesions > 40 mm (hazard ratio [HR], 1.53; p=0.046] and a NLR > 4 (HR, 1.75; p=0.009) were considered to be predictive markers of short PFS. A poor performance status (HR, 4.79; p < 0.001), a sum of target lesions > 40 mm (HR, 1.93; p=0.025), and an NLR > 4 (HR, 3.36; p < 0.001) were the significant predictors for poor survival. Conclusion ICIs exhibited favorable antitumor activity in R/M HNSCC. Clinically, our findings can be used to recognize patients benefit from receiving ICI.
참고문헌 (26)
- Colevas AD, "NCCN guidelines insights: head and neck cancers, version 1.2018", J Natl Compr Canc Netw, 16, pp.479~490 (2018)
- Vermorken JB, "Platinum-based chemotherapy plus cetuximab in head and neck cancer", N Engl J Med, 359, pp.1116~1127 (2008)
- Leon X, "A retrospective analysis of the outcome of patients with recurrent and", or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy, 2005, pp.17, 418~424
- "J Clin Oncol", 2009, 1864~1871
- Machiels JP, "Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamouscell carcinoma of the head and neck progressing on or after platinum-based therapy(LUX-Head & Neck 1) : an open-label, randomised phase 3 trial", Lancet Oncol, 16, pp.583~594 (2015)
- Gong J, "Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy : a comprehensive review of registration trials and future considerations", J Immunother Cancer, 6, pp.8~ (2018)
- Ferris RL, "Nivolumab for recurrent squamous-cell carcinoma of the head and neck", N Engl J Med, 375, pp.1856~1867 (2016)
- Cohen EE, "Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma(KEYNOTE-040) : a randomised, openlabel, phase 3 study", Lancet, 393, pp.156~167 (2019)
- Seiwert TY, "Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012) : an open-label, multicentre, phase 1b trial", Lancet Oncol, 17, pp.956~965 (2016)
- Stransky N, "The mutational landscape of head and neck squamous cell carcinoma", Science, 333, pp.1157~1160 (2011)
- Zandberg DP, "The role of the PD-L1 : PD-1 pathway in squamous cell carcinoma of the head and neck", Oral Oncol, 50, pp.627~632 (2014)
- Fancello L, "Tumor mutational burden quantification from targeted gene panels : major advancements and challenges", J Immunother Cancer, 7, pp.183~ (2019)
- Prat A, "Immune-related gene expression profiling after PD-1blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma", Cancer Res, 77, pp.3540~3550 (2017)
- Saloura V, "An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck", Cancer Chemother Pharmacol, 73, pp.1227~1239 (2014)
- Bauml J, "Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer : results from a single-arm, phase II study", J Clin Oncol, 35, pp.1542~1549 (2017)
- Joseph RW, "Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab", Clin Cancer Res, 24, pp.4960~4967 (2018)
- Katsurada M, "Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for nonsmall cell lung cancer", Anticancer Res, 39, pp.815~825 (2019)
- Bagley SJ, "Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer", Lung Cancer, 106, pp.1~7 (2017)
- Cao J, "Neutrophil-to-lymphocyte ratio predicts PSA response and prognosis in prostate cancer : a systematic review and meta-analysis", PLoS One, 11, pp.e0158770~ (2016)
- Cheng H, "The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients", Pancreatology, 16, pp.1080~1084 (2016)
- Faria SS, "The neutrophil-to-lymphocyte ratio : a narrative review", Ecancermedicalscience, 10, pp.702~ (2016)
- Sacdalan DB, "Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors : a review and meta-analysis", Onco Targets Ther, 11, pp.955~965 (2018)
- Finotello F, "New strategies for cancer immunotherapy : targeting regulatory T cells", Genome Med, 9, pp.10~ (2017)
- Zilio S, "Neutrophils and granulocytic MDSC : the janus god of cancer immunotherapy", Vaccines(Basel), 4, pp.31~ (2016)
- Brahmer JR, "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology clinical practice guideline", J Clin Oncol, 36, pp.1714~1768 (2018)
- Cohen EEW, "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck(HNSCC)", J Immunother Cancer, 7, pp.184~ (2019)